PMID- 32862535
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1601-0825 (Electronic)
IS  - 1354-523X (Linking)
VI  - 26 Suppl 1
DP  - 2020 Sep
TI  - Innovations for prevention and care of oral candidiasis in HIV-infected 
      individuals: Are they available?-A workshop report.
PG  - 91-102
LID - 10.1111/odi.13391 [doi]
AB  - Oral candidiasis (OC) is the most prevalent HIV-related oral lesion in patients 
      on combined anti-retroviral therapy (cART) or without cART. Management is 
      challenged in some patients by development of resistance to azole drugs, such as 
      fluconazole. Recent scientific knowledge about OC pathogenesis, the role of OC in 
      the immune reconstitution inflammatory syndrome (IRIS), the relationship of OC 
      with the microbiome, and novelties in OC treatment was discussed in an 
      international workshop format. Literature searches were conducted to address five 
      questions: (a) Considering the pathogenesis of Candida spp. infection, are there 
      any potential therapeutic targets that could be considered, mainly in 
      HIV-infected individuals resistant to fluconazole? (b) Is oral candidiasis part 
      of IRIS in HIV patients who receive cART? (c) Can management of the oral 
      microbiome reduce occurrence of OC in patients with HIV infection? (d) What are 
      the recent advances (since 2015) regarding plant-based and alternative medicines 
      in management of OC? and (e) Is there a role for photodynamic therapy in 
      management of OC in HIV-infected patients? A number of the key areas where 
      further research is necessary were identified to allow a deeper insight into this 
      oral condition that could help to understand its nature and recommend 
      alternatives for care.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights 
      reserved.
FAU - Ramirez-Amador, Velia
AU  - Ramirez-Amador V
AD  - Department of Health Care, Master s Course in Oral Pathology and Oral Medicine, 
      Universidad Autonoma Metropolitana-Xochimilco, Mexico City, Mexico.
FAU - Patton, Lauren L
AU  - Patton LL
AD  - Division of Craniofacial and Surgical Care, Adams School of Dentistry University 
      of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Naglik, Julian R
AU  - Naglik JR
AD  - Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & 
      Craniofacial Sciences, King's College London, London, UK.
FAU - Nittayananta, Wipawee
AU  - Nittayananta W
AD  - Faculty of Dentistry, Thammasat University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Oral Dis
JT  - Oral diseases
JID - 9508565
RN  - 0 (Antifungal Agents)
RN  - 8VZV102JFY (Fluconazole)
MH  - *Antifungal Agents/therapeutic use
MH  - *Candidiasis, Oral/drug therapy/prevention & control
MH  - Fluconazole/therapeutic use
MH  - *HIV Infections/complications/drug therapy
MH  - Humans
OTO - NOTNLM
OT  - Candida
OT  - HIV
OT  - anti-fungal therapy
OT  - immune reconstitution inflammatory syndrome
OT  - microbiome
OT  - probiotics
EDAT- 2020/08/31 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/08/31 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1111/odi.13391 [doi]
PST - ppublish
SO  - Oral Dis. 2020 Sep;26 Suppl 1:91-102. doi: 10.1111/odi.13391.